LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Comparative Nectary Morphology across Cleomaceae (Brassicales).

    Zenchyzen, Brandi / Weissner, Stacie / Martin, Jaymie / Lopushinsky, Ainsley / John, Ida / Nahal, Ishnoor / Hall, Jocelyn C

    Plants (Basel, Switzerland)

    2023  Volume 12, Issue 6

    Abstract: Floral nectaries have evolved multiple times and rapidly diversified with the adaptive radiation of animal pollinators. As such, floral nectaries exhibit extraordinary variation in location, size, shape, and secretory mechanism. Despite the intricate ... ...

    Abstract Floral nectaries have evolved multiple times and rapidly diversified with the adaptive radiation of animal pollinators. As such, floral nectaries exhibit extraordinary variation in location, size, shape, and secretory mechanism. Despite the intricate ties to pollinator interactions, floral nectaries are often overlooked in morphological and developmental studies. As Cleomaceae exhibits substantial floral diversity, our objective was to describe and compare floral nectaries between and within genera. Floral nectary morphology was assessed through scanning electron microscopy and histology across three developmental stages of nine Cleomaceae species including representatives for seven genera. A modified fast green and safranin O staining protocol was used to yield vibrant sections without highly hazardous chemicals. Cleomaceae floral nectaries are most commonly receptacular, located between the perianth and stamens. The floral nectaries are supplied by vasculature, often contain nectary parenchyma, and have nectarostomata. Despite the shared location, components, and secretory mechanism, the floral nectaries display dramatic diversity in size and shape, ranging from adaxial protrusions or concavities to annular disks. Our data reveal substantive lability in form with both adaxial and annular floral nectaries interspersed across Cleomaceae. Floral nectaries contribute to the vast morphological diversity of Cleomaceae flowers and so are valuable for taxonomic descriptions. Though Cleomaceae floral nectaries are often derived from the receptacle and receptacular nectaries are common across flowering plants, the role of the receptacle in floral evolution and diversification is overlooked and warrants further exploration.
    Language English
    Publishing date 2023-03-10
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2704341-1
    ISSN 2223-7747
    ISSN 2223-7747
    DOI 10.3390/plants12061263
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.

    Glitza Oliva, Isabella C / Ferguson, Sherise D / Bassett, Roland / Foster, Alexandra P / John, Ida / Hennegan, Tarin D / Rohlfs, Michelle / Richard, Jessie / Iqbal, Masood / Dett, Tina / Lacey, Carol / Jackson, Natalie / Rodgers, Theresa / Phillips, Suzanne / Duncan, Sheila / Haydu, Lauren / Lin, Ruitao / Amaria, Rodabe N / Wong, Michael K /
    Diab, Adi / Yee, Cassian / Patel, Sapna P / McQuade, Jennifer L / Fischer, Grant M / McCutcheon, Ian E / O'Brien, Barbara J / Tummala, Sudhakar / Debnam, Matthew / Guha-Thakurta, Nandita / Wargo, Jennifer A / Carapeto, Fernando C L / Hudgens, Courtney W / Huse, Jason T / Tetzlaff, Michael T / Burton, Elizabeth M / Tawbi, Hussein A / Davies, Michael A

    Nature medicine

    2024  

    Language English
    Publishing date 2024-04-22
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-024-02998-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.

    Glitza Oliva, Isabella C / Ferguson, Sherise D / Bassett, Roland / Foster, Alexandra P / John, Ida / Hennegan, Tarin D / Rohlfs, Michelle / Richard, Jessie / Iqbal, Masood / Dett, Tina / Lacey, Carol / Jackson, Natalie / Rodgers, Theresa / Phillips, Suzanne / Duncan, Sheila / Haydu, Lauren / Lin, Ruitao / Amaria, Rodabe N / Wong, Michael K /
    Diab, Adi / Yee, Cassian / Patel, Sapna P / McQuade, Jennifer L / Fischer, Grant M / McCutcheon, Ian E / O'Brien, Barbara J / Tummala, Sudhakar / Debnam, Matthew / Guha-Thakurta, Nandita / Wargo, Jennifer A / Carapeto, Fernando C L / Hudgens, Courtney W / Huse, Jason T / Tetzlaff, Michael T / Burton, Elizabeth M / Tawbi, Hussein A / Davies, Michael A

    Nature medicine

    2023  Volume 29, Issue 4, Page(s) 898–905

    Abstract: There is a critical need for effective treatments for leptomeningeal disease (LMD). Here, we report the interim analysis results of an ongoing single-arm, first-in-human phase 1/1b study of concurrent intrathecal (IT) and intravenous (IV) nivolumab in ... ...

    Abstract There is a critical need for effective treatments for leptomeningeal disease (LMD). Here, we report the interim analysis results of an ongoing single-arm, first-in-human phase 1/1b study of concurrent intrathecal (IT) and intravenous (IV) nivolumab in patients with melanoma and LMD. The primary endpoints are determination of safety and the recommended IT nivolumab dose. The secondary endpoint is overall survival (OS). Patients are treated with IT nivolumab alone in cycle 1 and IV nivolumab is included in subsequent cycles. We treated 25 patients with metastatic melanoma using 5, 10, 20 and 50 mg of IT nivolumab. There were no dose-limiting toxicities at any dose level. The recommended IT dose of nivolumab is 50 mg (with IV nivolumab 240 mg) every 2 weeks. Median OS was 4.9 months, with 44% and 26% OS rates at 26 and 52 weeks, respectively. These initial results suggest that concurrent IT and IV nivolumab is safe and feasible with potential efficacy in patients with melanoma LMD, including in patients who had previously received anti-PD1 therapy. Accrual to the study continues, including in patients with lung cancer. ClinicalTrials.gov registration: NCT03025256 .
    MeSH term(s) Humans ; Nivolumab ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Melanoma/pathology ; Lung Neoplasms/drug therapy ; Treatment Outcome ; Ipilimumab
    Chemical Substances Nivolumab (31YO63LBSN) ; Ipilimumab
    Language English
    Publishing date 2023-03-30
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-022-02170-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top